Key Players and Competitive Dynamics in the Short-Acting Insulin Market

The short-acting insulin market is on track for notable expansion as demand for effective diabetes management solutions continues to rise. Driven by increasing prevalence of type 2 diabetes and advancements in insulin delivery, this market is set to experience steady growth through the end of the decade. Let's explore the market's growth projections, key players, emerging trends, and the breakdown of its segments.

Projected Market Growth and Size of the Short-Acting Insulin Market
The short-acting insulin market is expected to grow significantly over the coming years, reaching a market size of $14.87 billion by 2030. This expansion is forecasted at a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this upward trend include a rise in type 2 diabetes cases, increased reliance on insulin therapy, greater adoption of home-based diabetes care, innovations in insulin delivery technologies, and growing demand for fast-acting insulin formulations. Key trends anticipated during this period involve heightened interest in post-meal blood glucose control, broader use of rapid-acting insulin analogues, widespread adoption of pre-filled insulin pens, expansion of intensive insulin therapy programs, and a stronger emphasis on strict glycemic management.

Download a free sample of the short-acting insulin market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Shaping the Short-Acting Insulin Market Landscape
The short-acting insulin industry is dominated by several prominent pharmaceutical companies, including Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., and Aspen Pharmacare Holdings Limited.

In December 2024, India-based Lupin Limited acquired the Humulin product line from Eli Lilly & Company in India for an undisclosed sum. This strategic move aims to bolster Lupin's position in the Indian insulin market by incorporating Eli Lilly's Humulin insulin products into its portfolio. Eli Lilly, headquartered in the United States, is well-known for its expertise in insulin therapies, including short-acting insulin.

View the full short-acting insulin market report:
https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Innovations and Trends Driving the Short-Acting Insulin Market
Key players in the short-acting insulin market are focusing on developing innovative products such as interchangeable rapid-acting insulin biologics. These biologics are designed to improve glycemic control while offering patients greater flexibility with substitution options. Interchangeable rapid-acting insulin biologics refer to fast-acting insulin formulations approved by regulatory bodies that can replace equivalent insulin products without requiring a new prescription, facilitating easier diabetes management.

For example, in July 2025, Biocon Biologics, a biosimilars company based in both India and the United States, obtained FDA approval for Kirsty (insulin aspart xjhz). Kirsty is notable for being the first and only interchangeable rapid-acting insulin aspart available in the US. It is a biosimilar to NovoLog (insulin aspart) and has demonstrated no significant differences in safety, efficacy, purity, or potency based on clinical and analytical data. Kirsty comes in a 100 units/mL concentration and is available as a single-patient-use prefilled pen for subcutaneous use, as well as a multi-dose vial suitable for both subcutaneous and intravenous administration. This product aims to enhance glycemic control for both adults and children living with diabetes mellitus.

Detailed Segment Breakdown of the Global Short-Acting Insulin Market
This report segments the short-acting insulin market into several categories for a comprehensive understanding:

1) By Formulation: Regular Insulin, Rapid-Acting Insulin
2) By Dosage Form: Vials, Pre-filled Pens, Cartridges
3) By Route of Administration: Subcutaneous, Intravenous
4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes
5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Further detailed subsegments include:
- For Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin
- For Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

This granular segmentation provides insights into the diverse product types and delivery modes shaping the short-acting insulin market worldwide.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.